The EV-302 Study and the Implications for Metastatic Bladder Cancer Care
Interview with Cora Sternberg on the EV-302 study presented at ESMO 2023.
This study's results, showing a median overall survival of 32 months for
the EV and pembrolizumab arm, suggest a new standard of care for
metastatic urothelial cancer, significantly improving patient outcomes.
